Antibody-based immunotherapy of solid cancers: progress and possibilities.

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Monoclonal antibodies are key in novel cancer therapeutics, with properties determined by antigen specificity and constant regions.
• Advances in cancer biology and host-tumor interactions reveal new targets for antibody development.
• Checkpoint inhibitors have validated immune modulation as a successful therapeutic strategy.

Purpose of the Study:

• To review engineered monoclonal antibody products for personalized cancer treatment.
• To highlight targeting strategies for both tumor cells and the tumor microenvironment.
• To discuss the potential of antibodies in overcoming challenges posed by solid tumor stroma.

Main Methods:

• Review of current literature on monoclonal antibody development in oncology.
• Analysis of engineered antibody properties and their therapeutic implications.
• Comparison of challenges in treating solid tumors versus hematologic malignancies.

Main Results:

• Engineered monoclonal antibodies are emerging as central components of personalized cancer therapies.
• Targeting tumor stroma, which contains immune-dampening elements, is crucial for solid tumor treatment.
• Antibody engineering allows for tailored approaches to combat complex tumor biology.

Conclusions:

• Engineered monoclonal antibodies represent a significant advancement in personalized cancer treatment paradigms.
• The ability to target both tumor and stromal components offers a more comprehensive therapeutic strategy.
• This approach holds promise for improving outcomes in solid cancer patients by modulating the tumor microenvironment.